OpenURL Connection Search

Select item for more details and to access through your institution.

Primary analysis of JUMP, a phase 3b, expanded‐access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.
Published in:
British Journal of Haematology, 2020, v. 189, n. 5, p. 888, doi. 10.1111/bjh.16462
By:
- Al‐Ali, Haifa Kathrin;
- Griesshammer, Martin;
- Foltz, Lynda;
- Palumbo, Giuseppe A.;
- Martino, Bruno;
- Palandri, Francesca;
- Liberati, Anna Marina;
- Coutre, Philipp;
- García‐Hernández, Carmen;
- Zaritskey, Andrey;
- Tavares, Renato;
- Gupta, Vikas;
- Raanani, Pia;
- Giraldo, Pilar;
- Hänel, Mathias;
- Damiani, Daniela;
- Sacha, Tomasz;
- Bouard, Catherine;
- Paley, Carole;
- Tiwari, Ranjan
Publication type:
Article
ENESTop 192-Weeks Results: Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After Stopping Second-Line Nilotinib.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S288, doi. 10.1016/j.clml.2019.07.233
By:
- Mahon, Francois-Xavier;
- Boquimpani, Carla;
- Takahashi, Naoto;
- Benyamini, Noam;
- Clementino, Nelma Cristina D.;
- Shuvaev, Vasily;
- Lipton, Jeffrey H.;
- Turkina, Anna G.;
- De Paz Arias, Raquel;
- Moiraghi, Beatriz;
- Nicolini, Franck E.;
- Dengler, Jolanta;
- Sacha, Tomasz;
- Kim, Dong-Wook;
- Fellague-Chebra, Rafik;
- Tiwari, Ranjan;
- Bouard, Catherine;
- Hughes, Timothy P.
Publication type:
Article
ENESTop 144-Week Update: Long-Term Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After Stopping Second-Line Nilotinib.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S222, doi. 10.1016/j.clml.2018.07.092
By:
- Hughes, Timothy P.;
- Boquimpani, Carla;
- Takahashi, Naoto;
- Benyamini, Noam;
- Clementino, Nelma Cristina D.;
- Shuvaev, Vasily;
- Merchant, Akil;
- Lipton, Jeffrey H.;
- Turkina, Anna G.;
- De Paz Arias, Raquel;
- Moiraghi, Beatriz;
- Nicolini, Franck E.;
- Dengler, Jolanta;
- Sacha, Tomasz;
- Kim, Dong-Wook;
- Fellague-Chebra, Rafik;
- Acharya, Sandip;
- Chaturvedi, Shalini;
- Bouard, Catherine;
- Mahon, François-Xavier
Publication type:
Article
Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low‐, intermediate‐1‐, intermediate‐2‐, and high‐risk myelofibrosis in JUMP, a Phase 3b, expanded‐access study
Published in:
Hematological Oncology, 2021, v. 39, n. 4, p. 558, doi. 10.1002/hon.2898
By:
- Passamonti, Francesco;
- Gupta, Vikas;
- Martino, Bruno;
- Foltz, Lynda;
- Zaritskey, Andrey;
- Al‐Ali, Haifa Kathrin;
- Tavares, Renato;
- Maffioli, Margherita;
- Raanani, Pia;
- Giraldo, Pilar;
- Griesshammer, Martin;
- Guglielmelli, Paola;
- Bouard, Catherine;
- Paley, Carole;
- Tiwari, Ranjan;
- Vannucchi, Alessandro M.
Publication type:
Article

Found: 4

Primary analysis of JUMP, a phase 3b, expanded‐access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.

ENESTop 192-Weeks Results: Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After Stopping Second-Line Nilotinib.

ENESTop 144-Week Update: Long-Term Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After Stopping Second-Line Nilotinib.

Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low‐, intermediate‐1‐, intermediate‐2‐, and high‐risk myelofibrosis in JUMP, a Phase 3b, expanded‐access study